What is a normal TSH level on levothyroxine?
What is a normal TSH level, and what does it mean when you take levothyroxine?
For most adults, a normal TSH runs from about 0.4 to between 4 and 5 mIU/L, and on levothyroxine the usual goal is a TSH inside your lab's range. The American Thyroid Association (ATA) puts the therapeutic target at 0.4 to 4.0 mIU/L in primary hypothyroidism. MedlinePlus lists 0.4 to 4.8 µU/mL as normal. TSH comes from the pituitary gland and rises when thyroid hormone is low, so it is the main test used to follow levothyroxine. Regular checks show whether the dose is right. A TSH can be less useful when the pituitary is the source of the problem.
This is not clinical evidence and not medical advice. It does not replace your care team. Discuss anything here with your clinician before you act on it.
Arun Verma, co-founder of Triangle · Published · Updated
On levothyroxine, your TSH is read against a range that changes from lab to lab, and a dose change takes weeks to show up in it.
Why do normal TSH ranges differ from lab to lab?
Labs use different instruments, so the same blood can be printed against different ranges, and a result can sit in range on one report and just outside it on another. An ATA-commissioned review says TSH and free T4 results can differ by up to 50% depending on the reagents and equipment, and that labs may change instruments and reference intervals without alerting physicians. The printed upper edge varies too, from 4.0 to 4.8 across the sources used for this page. It also depends on age: MedlinePlus says some labs use an upper limit as high as 7 µU/mL for older people.
What TSH target is used on levothyroxine, and does it change with age?
On levothyroxine, a TSH is usually judged against the reference range for your age, which ATA's 2014 guideline generally recommends as the target range. A target in the lower third of the lab's range has also been proposed and may in general be reasonable, but the guideline notes it is not a universally endorsed approach. Reference ranges themselves run higher in older populations, such as people over 65, according to the same guideline. Symptoms alone are a poor guide to whether a dose is adequate, so they are followed alongside TSH rather than in place of it. You could ask how your own target is set, and whether it takes your age into account.
If you take levothyroxine after thyroid cancer, is your TSH target different?
It may be. After surgery for differentiated thyroid cancer, the ATA's 2025 thyroid cancer guideline recommends an individual decision on whether to keep TSH below the reference range, weighing potential benefits and risks. It says people with high-risk disease may be more likely to benefit than those with low-risk disease. It does not suggest long-term TSH suppression for low- or intermediate-risk disease with no evidence of recurrence, and says TSH goals should be re-evaluated over time. The guideline lists recognized risks of a low TSH, including atrial fibrillation and osteoporosis and possibly fracture in postmenopausal women. A 2026 scoping review of 35 studies found greater suppression was the most consistently reported treatment factor tied to adverse bone outcomes, with postmenopausal status a relatively consistent patient factor. Evidence for heart, metabolic and other outcomes was less extensive and less consistent. The review maps associations, not proof of cause. If your target was set years ago, you could ask your care team what your TSH goal is now and whether it still fits your cancer risk and bone health. Any dose change is their call.
How long does a dose change take to show up in your TSH?
Weeks. The usual first recheck comes 6 to 8 weeks after a dose is started or changed, and once a dose is working, the next check is probably in 6 months and then once a year. ATA's 2014 guideline says to reassess TSH 4 to 6 weeks after a change, so the sources differ by a couple of weeks. The pattern follows the medicine: T4 and TSH generally reach steady state about 6 weeks after therapy begins, and it can take weeks to months for a TSH to reflect an acute change. A fair question for your doctor is when the next TSH is due and which dose it will reflect.
Can switching levothyroxine products change your TSH?
It may. ATA's 2014 guideline favors staying on one formulation and says switches could potentially change the dose delivered, and the ATA rates the recommendation weak, on low-quality evidence for general populations. It also says a change in product should be followed by a TSH recheck. FDA describes a study of more than 15,000 monitored patients in which people who switched among generic products kept the same average TSH as people who used a single product. The study was not designed to test therapeutic equivalence. FDA notes that its conclusion conflicts with the guideline's recommendations. You could ask your pharmacist or doctor whether your product changed between two draws.
What else can move a TSH or free T4 result?
Beyond the dose, the test itself can be thrown off. ATA says biotin, a common supplement, can make several thyroid tests look abnormal when the blood levels are normal. Free T4 also shows a transient peak of about 15% roughly 4 hours after a levothyroxine dose, so you could ask whether the timing of your last pill relative to the draw matters for your report.
Do Hashimoto's antibody results change how TSH is read?
Following antibody levels over time is not helpful in detecting response to therapy, ATA says. TSH and free T4 are what tell about actual thyroid function. Hashimoto's disease is the most common cause of hypothyroidism, and thyroid peroxidase (TPO) antibodies are present in most people with it.
What could you ask your doctor about your TSH?
You could ask which range your lab uses and whether it changed since your last result, and how your target is set for your age. A fair question is when the next TSH is due and which dose or product it will reflect, and whether your dose or product changed between your last two results. A fair question is whether a medicine or a supplement such as biotin could have affected the test. Bringing earlier results from other labs can help show how your TSH has moved. What a given number means for you is a question for the clinician who knows your history.
Sources
- American Thyroid Association Task Force: Guidelines for the Treatment of Hypothyroidism, Thyroid 2014;24(12):1670-1751: The ATA's 2014 treatment guideline says a TSH value within the reference range (0.4-4.0 mIU/L) should be considered the therapeutic target in primary hypothyroidism, and that TSH is the most reliable marker of adequacy of replacement treatment (Recommendation 1b, discussion).
- MedlinePlus: TSH test (Medical Encyclopedia, review date 1/25/2026): MedlinePlus lists normal TSH as 0.4 to 4.8 microunits per milliliter (µU/mL).
- MedlinePlus: TSH test (Medical Encyclopedia, review date 1/25/2026): MedlinePlus says that if you are being treated for a thyroid disorder your TSH will likely be kept between 0.4 and 4.8 µU/mL, with listed exceptions that include when a pituitary disorder is the cause of the problem.
- MedlinePlus: TSH (Thyroid-stimulating hormone) Test: MedlinePlus says TSH tells the thyroid how much hormone to make, and that the pituitary gland makes larger amounts of TSH when the thyroid hormone level in the blood is too low.
- MedlinePlus: TSH (Thyroid-stimulating hormone) Test: MedlinePlus says that if you take prescription thyroid hormone medicine for hypothyroidism you will have regular TSH tests, done to check that you are taking the right dose of the medicine.
- American Thyroid Association: Adult Hypothyroidism (patient page): ATA's patient page says TSH is a hormone from the pituitary gland that tells the thyroid to work, and that if the pituitary is damaged the TSH test may not help.
- ATA-commissioned review: Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine), Thyroid 2023;33(9):1013-1028: The ATA-commissioned review says the same test reported by different manufacturers' instruments can differ in absolute value and requires appropriate reference intervals, and that laboratories may change instruments and reference intervals without consulting or alerting physicians (Box 1, p. 1014).
- ATA-commissioned review: Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine), Thyroid 2023;33(9):1013-1028: The ATA-commissioned review says that depending on the selected assay reagents and equipment, laboratory results may differ by up to 50% for both fT4 and TSH, and that if method-specific reference intervals are not employed the classification of a numerical result may be different depending on the assay used (p. 1019).
- MedlinePlus: TSH test (Medical Encyclopedia, review date 1/25/2026): MedlinePlus says some labs use a higher normal range limit for older people, even as high as 7 µU/mL.
- American Thyroid Association Task Force: Guidelines for the Treatment of Hypothyroidism, Thyroid 2014;24(12):1670-1751: The ATA's 2014 treatment guideline says a target TSH in the age-specific reference range is generally recommended (Recommendation 1b, discussion).
- American Thyroid Association Task Force: Guidelines for the Treatment of Hypothyroidism, Thyroid 2014;24(12):1670-1751: The ATA's 2014 treatment guideline says a target TSH in the lower tertile of the laboratory reference range has been proposed and may in general be reasonable, but is not a universally endorsed approach (Recommendation 1b, discussion).
- American Thyroid Association Task Force: Guidelines for the Treatment of Hypothyroidism, Thyroid 2014;24(12):1670-1751: The ATA's 2014 treatment guideline says normal serum TSH ranges are higher in older populations (such as those over 65 years) (Recommendation 6a).
- American Thyroid Association Task Force: Guidelines for the Treatment of Hypothyroidism, Thyroid 2014;24(12):1670-1751: The ATA's 2014 treatment guideline says symptoms alone lack sensitivity and specificity and are not recommended for judging adequacy of replacement in the absence of biochemical assessment, and that symptoms should be followed but considered in the context of serum TSH values (Recommendation 1c).
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer, Ringel MD et al., Thyroid 2025;35(8):841-985: The ATA's 2025 differentiated thyroid cancer guideline says individualization of decisions to initiate TSH suppression to below the reference range is recommended based on potential benefits and risks, recognizing that patients with high-risk disease may be more likely to benefit from a TSH in the subnormal range than those with low-risk disease (Recommendation 45; conditional recommendation, low certainty evidence).
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer, Ringel MD et al., Thyroid 2025;35(8):841-985: The ATA's 2025 differentiated thyroid cancer guideline says long-term TSH suppression is not suggested for patients with low- or intermediate-risk disease who have no evidence of biochemical or structural recurrence, and that risks versus benefits of TSH suppression and TSH goals should be re-evaluated over time (Recommendation 46A, conditional, low certainty evidence; 46B, Good Practice Statement).
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer, Ringel MD et al., Thyroid 2025;35(8):841-985: The ATA's 2025 differentiated thyroid cancer guideline says recognized adverse outcomes of a low TSH include increased risk for atrial fibrillation and stroke (especially in older patients) and increased risk of osteoporosis and possibly fracture in postmenopausal women (Recommendation 46, discussion).
- Jay M, Esttaifo F et al., Factors Associated with Adverse Effects of Postoperative TSH-Directed Levothyroxine Therapy in Adults with Differentiated Thyroid Cancer: A Scoping Review, Thyroid 2026 (supporting evidence): The 2026 Thyroid scoping review included 35 studies (11,819 patients) and says greater suppression intensity was the most consistently reported treatment-related factor associated with adverse skeletal outcomes, postmenopausal status emerged as a relatively consistent patient-level factor, and evidence for cardiometabolic, neuropsychological, reproductive, and muscular outcomes was less extensive and less consistent (abstract).
- American Thyroid Association: Adult Hypothyroidism (patient page): ATA's patient page says your doctor will check your blood 6 to 8 weeks after starting or changing your thyroid hormone dose.
- NIDDK: Hypothyroidism (Underactive Thyroid) (last reviewed March 2021): NIDDK says your doctor will give you a blood test about 6 to 8 weeks after you begin levothyroxine, adjusting the dose if needed, and that each time the dose is adjusted you will have another blood test.
- NIDDK: Hypothyroidism (Underactive Thyroid) (last reviewed March 2021): NIDDK says once you have reached a dose that is working, your doctor will probably repeat the blood test in 6 months and then once a year.
- American Thyroid Association Task Force: Guidelines for the Treatment of Hypothyroidism, Thyroid 2014;24(12):1670-1751: The ATA's 2014 treatment guideline says steady-state levels of T4 and TSH are generally achieved in 6 weeks (approximately five to six half-lives) after initiation of therapy (Recommendation 1a, discussion).
- American Thyroid Association Task Force: Guidelines for the Treatment of Hypothyroidism, Thyroid 2014;24(12):1670-1751: The ATA's 2014 treatment guideline recommends thyrotropin assessment 4-6 weeks after any dosage change (Recommendation 4b).
- ATA-commissioned review: Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine), Thyroid 2023;33(9):1013-1028: The ATA-commissioned review says it may take weeks to months for the TSH measurement to accurately reflect thyroid status after an acute change (Box 1, p. 1014).
- American Thyroid Association Task Force: Guidelines for the Treatment of Hypothyroidism, Thyroid 2014;24(12):1670-1751: The ATA's 2014 treatment guideline advises prescription of brand-name levothyroxine, or maintenance of the same generic preparation (an identifiable formulation), noting that switches between levothyroxine products could potentially result in variations in the administered dose; it rates this a weak recommendation, low-quality evidence, for general populations (Recommendation 2a).
- American Thyroid Association Task Force: Guidelines for the Treatment of Hypothyroidism, Thyroid 2014;24(12):1670-1751: The ATA's 2014 treatment guideline says a change in an identifiable formulation of levothyroxine (brand name or generic) should be followed by re-evaluation of serum TSH at steady state (Recommendation 3d).
- FDA, Spotlight on CDER Science: A Real-World Case Study of Levothyroxine Use Addresses Institutional Concerns About Generic Product Interchangeability (content current as of 05/05/2022): FDA's Spotlight on CDER Science says an FDA-sponsored study of more than 15,000 monitored patients found those who switched among generic levothyroxine products maintained the same average serum thyrotropin level as those who consistently used a single product.
- FDA, Spotlight on CDER Science: A Real-World Case Study of Levothyroxine Use Addresses Institutional Concerns About Generic Product Interchangeability (content current as of 05/05/2022): FDA's Spotlight on CDER Science says the researchers pointed out their study was not designed to assess therapeutic equivalence of levothyroxine products, and that the conclusion conflicts with ATA guideline recommendations that warn clinicians about changes in thyroid function with product switching.
- American Thyroid Association: Thyroid Function Tests (patient page): ATA's Thyroid Function Tests page says biotin, a commonly taken over-the-counter supplement, can cause several thyroid function tests to appear abnormal when they are in fact normal in the blood.
- American Thyroid Association Task Force: Guidelines for the Treatment of Hypothyroidism, Thyroid 2014;24(12):1670-1751: The ATA's 2014 treatment guideline says that with levothyroxine there will be a transient peak in serum T4 and free T4 levels of about 15% magnitude about 4 hours after administration (Recommendation 1a, discussion).
- NIDDK: Hashimoto's Disease (last reviewed June 2021): NIDDK says Hashimoto's disease is the most common cause of hypothyroidism, and that thyroid peroxidase (TPO) antibodies are present in most people with Hashimoto's disease.
- American Thyroid Association: Thyroid Function Tests (patient page): ATA's Thyroid Function Tests page says that following thyroid antibody levels over time is not helpful in detecting the development of hypothyroidism or response to therapy, and that TSH and free T4 tell us about the actual thyroid function.
- MedlinePlus: TSH test (Medical Encyclopedia, review date 1/25/2026): MedlinePlus says to ask your health care provider about any medicines you are taking that may affect the test results.
Start your 7-day free trialThyra is made by Triangle. 7-day free trial, then $9 a month. Cancel anytime.